World of DTC Marketing
JULY 17, 2022
A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . It has to persuade patients to sign up for some heinous side effects.
Pharmaceutical Technology
DECEMBER 7, 2022
On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Celeritas
SEPTEMBER 26, 2022
The QR code payment market is projected to rise to $35 billion by 2030. Many hospitals want to support their physicians in expanding their expertise by providing useful educational resources. This will confirm the company name alongside the date of expiry, contents, and possible side effects. Training and Engagement: .
PM360
AUGUST 9, 2022
billion in 2030 at a CAGR of 9.2%. Levrx also engages physician groups and members directly, giving healthcare consumers the information needed at the point of care to keep costs low, avoid prescription rewrites, and prevent cost-related non-adherence. from 2021 and reach $4.2 billion in 2025. Furthermore, it is estimated to reach $6.5
Clarivate
AUGUST 17, 2022
Grace tells us about her experience as a physician and discusses healthcare literacy and education at the point of care. In 2017, the same year the SDGs came into effect, the United Nations found that less than half of the global population was covered by essential health services. Supporting patients at the point of care.
Clarify Health
OCTOBER 3, 2023
The data collected from these devices can help patients make more informed decisions about their health, have data-driven conversations with their physicians, and may even contribute to healthcare research in the future. billion by 2030, according to Grand View Research, Inc., and reported by Bloomberg.
pharmaphorum
SEPTEMBER 16, 2022
The company hopes to show in its phase 3 trial that GMRx2 can boost adherence, increase efficacy, and reduce side effects, compared to antihypertensive medicines given separately, and is targeting a launch of the drug in 2023. By 2030, it is projected that over 215 million Africans will have hypertension.
Expert insights. Personalized for you.
209 
Let's personalize your content